Clinical Trial Vanguard

1 week ago | clinicaltrialvanguard.com | Moe Alsumidaie

At the 2025 Veeva R&D and Quality Summit Europe, Marta Jureczko-Hinzmann, Senior Director of Global Clinical Solutions at AstraZeneca, shared how the company is transforming sponsor-site collaboration through the adoption of Site Connect. As part of AstraZeneca’s bold 2030 ambition—to launch 20 new medicines and become carbon negative—streamlining clinical trial operations has become essential.

1 week ago | clinicaltrialvanguard.com | Moe Alsumidaie

In 2025, a surge of FDA guidance updates signaled a broader shift in the clinical trial ecosystem. They marked a directional shift in how innovation, flexibility, and operational responsiveness are expected to manifest in regulated development environments. On paper, FDA guidances are intended to be non-binding recommendations. In practice, it tends to privilege sponsors who can interpret and act quickly, a structural phenomenon.

2 weeks ago | clinicaltrialvanguard.com | Moe Alsumidaie

At the 2025 Veeva R&D and Quality Summit Europe, Martin Helling, Executive Director of the One Medicine Platform at Boehringer Ingelheim, described how the company redefined industry benchmarks by launching a unified digital transformation across Clinical Operations, Clinical Data Management, Regulatory, and Quality—all at once. The One Medicine Platform is a company-wide initiative aimed at streamlining systems, harmonizing processes, and promoting a cultural shift toward standardization.

2 weeks ago | clinicaltrialvanguard.com | Moe Alsumidaie

Artificial intelligence (AI) is reshaping clinical trials, offering new efficiencies and insights. Rohit Nambisan, CEO of Lokavant, shares his expertise on AI’s role in optimizing clinical operations. This discussion explores AI’s potential, challenges, and future impact on the industry, providing valuable insights for researchers, sponsors, and patients. Rohit Nambisan: AI’s potential in clinical operations lies in automating laborious tasks, allowing experts to focus on strategic decision-making.

3 weeks ago | clinicaltrialvanguard.com | Moe Alsumidaie

In this interview with Dr. Seema Rajsingh, Executive Medical Director and Jarem Edwards, Clinical Scientist – Early Drug Development of Pi Health, a health technology and clinical research company transforming global access to innovative medicines and clinical trials through its proprietary AI-powered technology platform, we explore the challenges and opportunities in India’s oncology trial landscape. Despite housing 20% of the global population, India conducts only 2% of global oncology trials.